Dermatologicals
Refine search
Pharmaceutical
Spanish dermatology specialist Almirall today inaugurated new offices in Jing’an, Shanghai, establishing a presence dedicated to life science innovation and business development in medical dermatology in China, complementary to its in-house R&D in Barcelona. 12 March 2026
Biotechnology
Belgium’s largest drugmaker UCB has announced positive topline data from the BE BOLD trial assessing Bimzelx bimekizumab) versus Skyrizi (risankizumab) in adults living with active psoriatic arthritis (PsA). 11 March 2026
Pharmaceutical
Medicus Pharma has announced top-line results from its Phase II study of doxorubicin microneedle array (D-MNA) to non-invasively treat basal cell carcinoma (BCC) of the skin. 5 March 2026
Pharmaceutical
Priovant Therapeutics today announced that the US Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for brepocitinib for the treatment of dermatomyositis (DM) and has granted the application Priority Review. 3 March 2026
Pharmaceutical
The European Medicines Agency’s (EMA) human medicines committee (CHMP) recommended 6 novel medicines for approval at its February 2026 meeting. These now have to be approved by the European Commission, which usually takes two months or so. 27 February 2026
Biotechnology
Swiss dermatology focused biopharma Galderma today announced new data from the OLYMPIA open-label extension study investigating the long-term safety and efficacy of Nemluvio (nemolizumab) in moderate-to-severe prurigo nodularis. 27 February 2026
Biotechnology
US biopharma company Incyte’s UK subsidiary today announces that the National Institute for Health and Care Excellence (NICE) has approved the reimbursement of Opzelura (ruxolitinib) cream 15mg/g for eligible patients with non-segmental vitiligo on the National Health Service (NHI). 24 February 2026
Pharmaceutical
Spanish dermatology-focused pharma Almirall reported full-year 2025 net sales of 1.1 billion euros ($1.2 billion), up 12%, as total revenue rose 13% to 1.1 billion euros. EBITDA increased 21% to 233 million euros, while net income climbed to 46 million euros from 10 million euros a year earlier. 23 February 2026
Biotechnology
US drugmaker Eli Lilly has announced positive top-line results from the landmark TOGETHER-PsO open-label Phase IIIb trial evaluating the concomitant use of Taltz (ixekizumab) and Zepbound (tirzepatide) compared to Taltz alone in adults with moderate-to-severe plaque psoriasis and obesity or overweight with at least one additional weight-related comorbid condition. 19 February 2026
Pharmaceutical
US pharma giant Merck & Co and hospital system Mayo Clinic have announced a research and development agreement to apply artificial intelligence (AI), advanced analytics and multimodal clinical data, to support drug discovery and development. 19 February 2026
Pharmaceutical
Swiss pharma giant Novartis has announced positive topline results from its pivotal Phase III RemIND trial of oral remibrutinib in chronic inducible urticaria (CIndU). 18 February 2026
Biotechnology
US clinical-stage biotech Evommune has entered into a securities purchase agreement to sell 4,494,279 shares of its common stock to a select group of new and existing mutual funds and dedicated healthcare institutional investors in a private placement. 16 February 2026
Pharmaceutical
US dermatology specialist Verrica Pharmaceuticals has announced the appointment of Chris Chapman as its chief commercial officer (CCO). 13 February 2026
Pharmaceutical
US dermatologics specialist Verrica Pharmaceuticals) today announced the launch of Ycanth in Japan by its partner, Torii Pharmaceutical, a wholly-owned subsidiary of Japan’s Shionogi, for the treatment of molluscum contagiosum (molluscum). 9 February 2026
Biotechnology
The Roivant Sciences subsidiary Priovant Therapeutics has announced positive results from the Phase II BEACON study of brepocitinib in cutaneous sarcoidosis (CS). 9 February 2026
Biotechnology
USA-based clinical-stage dermatology start-up Veradermics has announced the pricing of its upsized initial public offering of 15,077,647 shares of its common stock at an initial public offering price of $17.00 per share. All of the shares are being offered by Veradermics. 5 February 2026
Biosimilars
Russian drugmaker Binnopharm Group together with China’s Mabwell announced plans to localize the production of a monoclonal antibody (MAb)-based drug for the treatment of asthma and atopic dermatitis in Russia. 4 February 2026
Biotechnology
Belgium’s largest drugmaker UCB today announced three-year data from the BE HEARD trials^ for Bimzelx (bimekizumab) in moderate to severe HS. 4 February 2026
Biotechnology
US clinical-stage biotech Sagimet Biosciences’ shares rose 10% to $6.23 after it announced that China-based partner Ascletis Pharma reported positive top-line results in the open-label Phase III trial evaluating the long-term safety of ASC-40 (denifanstat) tablets in patients with moderate to severe acne. 3 February 2026
Biotechnology
The US Food and Drug Administration (FDA) last week lifted the clinical hold on Intellia Therapeutics’ investigational new drug (IND) for its nexiguran ziclumeran (nex-z) for amyloidosis. The US Centers for Medicare and Medicaid Services (CMS) has released the names of 15 more drugs for a third cycle of Medicare price negotiations. On the deal-making front, Moderna signed a commercialization collaboration with Italy’s Recordati on mRNA-3927, and Japan’s Kyowa Kirin revealed that its partner Amgen has terminated the collaboration on dermatology candidate rocatinlimab. 1 February 2026
Biosimilars
South Korean biosimilars company Samsung Bioepis today announced that two new study results for SB17, a proposed biosimilar to Stelara (ustekinumab), marketed by Johnson & Johnson, will be presented at the 19th Congress of European Crohn’s and Colitis Organization (ECCO) being held from February 21 to 24 in Stockholm, Sweden. 22 February 2024
Biotechnology
RAPT Therapeutics revealed that the US Food and Drug Administration (FDA) has verbally notified the company that a clinical hold has been placed on the company’s Phase IIb trial of zelnecirnon (RPT193) in atopic dermatitis and its Phase IIa trial in asthma. 20 February 2024
Biotechnology
Spain’s Almirall has entered into an exclusive license agreement with Novo Nordisk for rights to the IL-21 blocking monoclonal antibody, NN-8828. 19 February 2024
Pharmaceutical
Spanish dermatology company Almirall has announced its annual 2023 financial results. 19 February 2024
Biotechnology
The US Food and Drug Administration (FDA) has approved the Biologics License Application (BLA) for Amtagvi (lifileucel) suspension for intravenous infusion, submitted by US biotech Iovance Biotherapeutics. 19 February 2024
Biotechnology
The Ministry of Health, Labor and Welfare (MHLW) in Japan has granted marketing and manufacturing authorization for Dupixent (dupilumab) for the treatment of chronic spontaneous urticaria (CSU) in people aged 12 years and older whose disease is not adequately controlled with existing therapy. 16 February 2024
Pharmaceutical
San Diego, USA-based precision oncology company Erasca announced two clinical trial collaboration and supply agreements (CTCSAs) with Swiss pharma giant Novartis for the MEK inhibitor Mekinist (trametinib). 15 February 2024
Biotechnology
French pharma major Sanofi is angry that its interleukin (IL)-13 and IL-4 blocking antibody Dupixent (dupilumab) has been recommended for the treatment of moderate-to-severe prurigo nodularis (PN) in Scotland but not in England and Wales. 14 February 2024
Biotechnology
Immuno-dermatology company Alys Pharmaceuticals has launched with an R&D pipeline enabled by multiple platform technologies and a $100 million financing by healthcare-focused investment firm Medicxi. 12 February 2024
Biotechnology
Belgian drugmaker UCB is closing in on another approval with its monoclonal IgG1 antibody, bimekizumab. 9 February 2024
Pharmaceutical
US pharma major Eli Lilly posted its fourth-quarter and full-year financial results on Tuesday. 6 February 2024
Pharmaceutical
American dermatology company Verrica Pharmaceuticals has filed a lawsuit against Canada’s Dormer Laboratories related to the active ingredient cantharidin. 5 February 2024
Biotechnology
Regeneron Pharmaceuticals’ shares were up 2.2% at $951.66 pre-market today, after it announced financial results for the fourth quarter and full year 2023. 2 February 2024
Biotechnology
Chinese biopharma Hutchmed today announced that Hong Kong-based Inmagene Biopharmaceuticals has exercised options to license two drug candidates discovered by Hutchmed. 2 February 2024
Pharmaceutical
UK-based dermatology company SkinBioTherapeutics is to acquire the issued share capital of Dermatonics, a specialist in innovative topical and dermatological products in the skincare and woundcare space. 25 January 2024
Pharmaceutical
Privately-held Danish dermatology specialist LEO Pharma has announced positive results from the DELTA FORCE trial. 24 January 2024
Pharmaceutical
Privately-held Danish dermatology specialist LEO Pharma says it has finalized the acquisition of the strategic asset TMB-001 as well as certain other assets from Timber Pharmaceuticals following the US firm’s Chapter 11 bankruptcy filing. 23 January 2024
Biotechnology
Last Tuesday, US biotech Aclaris Therapeutics announced that its chief executive would be stepping down and that the company is undertaking a review of its business and development of its dermatology candidates ATI-1777 and ATI-2138. US biotech Allakos suffered a further set back with its lirentelimab in trials for dermatitis and urticaria, leading to a decision to discontinue development. US biotech BridgeBio Pharma has agreed a deal to add up to $1.25 billion to its cash pile in a bid to progress its cardiovascular candidate acoramidis. Dutch biotech argenx gained Japanese approval for its myasthenia gravis drug Vyvdura/Vyvgart. 21 January 2024
Biotechnology
California, USA-based biotech Allakos yesterday announced disappointing top-line data from its Phase II clinical trial in patients with atopic dermatitis (ATLAS) and from its Phase IIb clinical trial in patients with chronic spontaneous urticaria (MAVERICK). 17 January 2024
Biotechnology
Shares of US clinical-stage biotech Aclaris Therapeutics shot up as much as 40% to $1.21 in early trading today, after it announced leadership changes and that it is undertaking a strategic review of its business. 16 January 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2026
| Headless Content Management with Blaze